Rosuvastatin is a new HMG‐CoA reductase inhibitor with unique pharmacologic and
pharmacokinetic properties. It has additional HMG‐CoA reductase enzyme‐binding …

This double-blind study to evaluate long-term efficacy and safety of atorvastatin was
performed in 31 community-and university-based research centers in the USA to directly …

Synopsis Pravastatin is an HMG-CoA reductase inhibitor which reduces plasma cholesterol
levels by inhibiting de novo cholesterol synthesis and increasing the receptor-mediated …

This analysis assessed the safety of atorvastatin in the 10-to 80-mg dose range using
pooled data from 44 completed trials comprising 16,495 dyslipidemic patients treated with …

Synopsis Fluvastatin, a member of the group of drugs known as HMG-CoA reductase
inhibitors, is used in the treatment of patients with hypercholesterolemia. In clinical trials in …

Clearance of atorvastatin occurs through hepatic uptake by organic anion transporting
polypeptides (OATPs) and subsequent metabolism by cytochrome P450 (CYP) 3A4. To …

Pharmacokinetic coadministration experiments with atorvastatin (ATV) and rifampicin (RIF)
in rats were performed to investigate the potential involvement of hepatic uptake …

In the work of Hedman et al 1 recently presented in the journal, a 10-fold higher systemic
exposure of pravastatin combined with unaffected terminal half-life was observed in …

A rapid and sensitive high-performance liquid chromatographic method was validated and
described for determination of atorvastatin in human serum. Following liquid–liquid …

The pharmacokinetics of fluvastatin, a potent inhibitor of hydroxymethylglutaryl‐CoA
reductase and thus cholesterol synthesis, have been studied in 24 normal male volunteers …